ReviewBiochimica et biophysica acta2013
Natural products: a continuing source of novel drug leads.
Review in Biochimica et biophysica acta, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 887 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
887 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- In Vitro Antiproliferative Activity in Plants of the GenusMolecules (Basel, Switzerland) · 2025Pooled it
- Targeting ferroptosis unveils a new era for traditional Chinese medicine: a scientific metrology study.Frontiers in pharmacology · 2024Pooled it
- Therapeutic Potential of Bioactive Compounds fromNutrients · 2023Pooled it
- High diversity but limited expression of biosynthetic gene clusters in a peatland microbial community.Nature communications · 2026Article
- Graphene Quantum Dots in Neurodegeneration: Protein Aggregation and the Microglial State as Therapeutic Targets.Nanomaterials (Basel, Switzerland) · 2026Review
- Synthesis, Antifungal Activity, and Plant Systemic Mobility of Amino Acid Conjugates of a Thiasporine A-Derived Phenylthiazole Scaffold.Molecules (Basel, Switzerland) · 2026Article
- Integrative multi-transcriptomics and network pharmacology reveal natural therapeutics as anti-cancer agents targeting AURKA for ovarian cancer treatment.Journal, genetic engineering & biotechnology · 2026Article
- Pharmacological Effects of Natural Products: Antioxidant, Anti-Inflammatory and Anticancer Activities.Molecules (Basel, Switzerland) · 2026Article
- Bioactive Natural and Synthetic Chalcones: Brazil as a Research Powerhouse in Discovery and Innovation.ChemMedChem · 2026Review
- A novel synergistic phycobiliprotein combination against HIV-1 shows potent antiviral activity.AMB Express · 2026Article
- Plant-Based Therapeutics Against Communicable Diseases: A Review of Ethnopharmacology and Medicinal Chemistry Approaches.Chemistry & biodiversity · 2026Review
- Lathyrane Diterpenoids: Half-Century of Chemical Insights and Therapeutic Potential.Plants (Basel, Switzerland) · 2026Review
- Silver-loaded nanoemulsion of Nepeta glomerulosa extract enhances cytotoxicity and induces apoptosis in A549 and AGS cancer cells.Journal of the Egyptian National Cancer Institute · 2026Article
- Article
- Breaking the Efflux Barrier: P-Glycoprotein and Emerging Strategies to Overcome Multidrug Resistance in Cancer.Cancers · 2026Review
- Gallic Acid Enhances Carboplatin-Induced Antitumoral Responses in Cervical Cancer Cells Through Oxidative Stress-Associated Mitochondrial and Apoptotic Mechanisms.Biomedicines · 2026Article
- Special Issue "Recent Advances of Natural Products in Chemical and Biological Aspects".International journal of molecular sciences · 2026Article
- Antibacterial and Anticancer Potential ofInternational journal of molecular sciences · 2026Article
- Review
- UCHL1 promotes osteosarcoma progression via deubiquitination and stabilization of LDHB.Discover oncology · 2026Article
827 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundNature has been a source of medicinal products for millennia, with many useful drugs developed from plant sources. Following discovery of the penicillins, drug discovery from microbial sources occurred and diving techniques in the 1970s opened the seas. Combinatorial chemistry (late 1980s), shifted the focus of drug discovery efforts from Nature to the laboratory bench. SCOPE OF REVIEW: This review traces natural products drug discovery, outlining important drugs from natural sources that revolutionized treatment of serious diseases. It is clear Nature will continue to be a major source of new structural leads, and effective drug development depends on multidisciplinary collaborations. MAJOR
conclusionsThe explosion of genetic information led not only to novel screens, but the genetic techniques permitted the implementation of combinatorial biosynthetic technology and genome mining. The knowledge gained has allowed unknown molecules to be identified. These novel bioactive structures can be optimized by using combinatorial chemistry generating new drug candidates for many diseases. GENERAL SIGNIFICANCE: The advent of genetic techniques that permitted the isolation / expression of biosynthetic cassettes from microbes may well be the new frontier for natural products lead discovery. It is now apparent that biodiversity may be much greater in those organisms. The numbers of potential species involved in the microbial world are many orders of magnitude greater than those of plants and multi-celled animals. Coupling these numbers to the number of currently unexpressed biosynthetic clusters now identified (>10 per species) the potential of microbial diversity remains essentially untapped.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.